British GlaxoSmithKline Plc. presented at the American Diabetes Association Congress in New Orleans, a Phase II study of experimental drug to treat diabetes Typo 2 Syncria (Albiglutide) where it showed significantly reduction of glucose levels as well as weight loss, in its weekly, 15 days and monthly dose. Comparative with Byetta Metformina and placebo. Details

US Merck & Co. Said that the initial results of a Phase III pivotal study of experimental drug Rolofylline drug to treat acute heart failure, did not meet primary nor secondary objectives.

US Johnson & Johnson said to analysts that they will seek Food and Drug Administration approval this year to treat premature ejaculation Dapoxitene, marketed in Europe as Priligy. Details

At the 14th.Congress of the European Hematology Association (EHA) in Berlin, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) presented a head to head 12 month comparative study of Novartis AG Tasigna (Nilotinib) and Gleevec/Glivec (Imatinib) drugs in newly diagnosed patients with chronic myeloid leukaemia (CML), with Philadelphia positive chromosome.

Johnson & Johnson Inc. presented data on experimental drug known as TCM 207, if added to a cocktail of therapies of other TB drugs, it is five times more effective treating resistant tuberculosis.

At the American Society for Clinical Oncology Congress (ASCO) that took place in Orlando, Florida, British GlaxoSmithKline Plc. presented clinical data on experimental Armala (Pazopanib) drug indicated to reduce tumor progression or death by 54 percent in advanced kidney cancer patients.

German Bayer AG and Onxy Pharmaceuticals announced initiation of Phase III trial to prove effectiveness in non-small cell lung cancer drug.

German Bayer AG and Swiss Roche Holding AG, announced Phase III clinical trial to test a combined drug of Nexavar (Sorafenib) and Tarceva (Erlotinib) to treat advanced hepatocellular carcinoma.

During the Congress of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida, Novartis AG presented data for its Phase IIIb drug, Sandostatin (octreotide acetate for injectable suspension) to treat patients with metastatic neuroendocrine tumors (NET)

Swiss Roche Holding AG presented at the American Society of Clinical Oncology Congress (ASCO) that is taken place in Orlando, Florida. Data from its experimental drug Trastuzumab-DM1, to treat aggressive breast cancer HER2+.

London-based GlaxoSmithKline Plc and biopharmaceutical Therevance Inc, presented positive results from the Phase IIb for experimental long-acting beta agonist (LABA) GW642444 (444) indicated to treat patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Danish Drug maker Lundbeck A/S announced that its experimental drug to treat alcoholism dependence Nalmefene initiates Phase III clinical trial, as it demonstrated in previous studies the ability to significantly limit the patient’s average alcohol intake. The drug test will enroll 1,800 patients

Novartis AG presented at the 50th Annual Meeting of the American Society of Hematology data of chronic myeloid leukemia drug Tasigna (nilotinib), approved to treat patients with chronic myeloid leukemia who are resistant to prior treatment with Glivec. Nearly 96 percent of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) achieved a complete cytogenetic response (CCyR) after six months of Tasigna treatment.

Merck & Co announced that in a Phase III clinical trial, investigational telcagepant significantly relieved moderate-to-severe migraine attacks and caused fewer side effects than the widely-used migraine drug Astra Zeneca’s Zomig (zolmitriptan)

J&J acquired Omrix Biopharmaceuticas in $438 million dollars seeking to expand it’s biosurgical and immunotherapy product portfolio.

Roche Holding AG said that oncology treatment Avastin met its primary endpoint in a Phase III breast cancer trial, increasing the time that the patients lived without worsening. Avastin was tested in combination with taxane-based, anthracycline-based or capecitabine chemotherapies

In a sample of 416 individuals with mild to moderate forms of the disease, Merck & Co. investigational compound MK-677, a drug that raises levels of a natural growth hormone, failed to improve memory skills in people with mild to moderate Alzheimer's disease. The findings were published in the Neurology journal.

Brussels-based chemical and pharmaceutical company Solvay anticipated the end of research and development on their experimental drug SLV 319 a cannabinoid type 1 receptor inhibitor (CB1), to treat obesity. The compound belongs to the same family of drugs as Sanofi-Aventis’s Acomplia, approved treatment that was withdrawn from the European market last month.